Gastroenterologie
a hepatologie

Elafibranor in the second-line treatment of primary biliary cholangitis

Soňa Fraňková ^{Orcid.org  1}

+ Affiliation
¹ Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha

Summary

Primary biliary cholangitis (PBC) is a chronic, autoimmune disorder of the liver. In its long-term course, it leads to small bile ducts destruction, cholestasis, liver fibrosis, cirrhosis and chronic liver failure. PBC is much common in women, especially of middle age. Most patients are diagnosed in an asymptomatic stage. The diagnosis is based on the combination of laboratory assessments, alkaline phosphatase elevation of more than 1,5 ULN for more than 6 months, and AMA antibodies in a titre 1: 40 or higher. The typical histological finding confirms the diagnosis, but the stage of liver disease may be determined based on the non-invasive liver stiffness measurement. Ursodeoxycholic acid represents nowadays standard-of-care in PBC patients, followed by elafibranor in intolerant patients or in non-responders. Liver transplantation is indicated in those with liver failure in whom conservative therapy failed.

Keywords

primary biliary cholangitis, AMA antibodies, alkaline phosphatase, kyselina ursodeoxycholová, obeticholic acid, liver transplantation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Eksteen B. Predicting risk in primary biliary cholangitis. Hepatology 2016; 63(3): 697–699. doi: 10.1002/hep.28377.
2. Addison T, Gull W. On a certain affection of the skin-vitiligoidea-α plana, ß tuberosa. Guy’s Hosp Rep 1851; 7: 265–276.
3. Hanot V. Etude sur une forme de cirrhose hypertrophique du foie (cirrhose hypertrophique avec ictere chronique). Paris: J.-B. Baillere 1876.
4. Mac MH, Thannhauser SJ. Xanthomatous biliary cirrhosis; a clinical syndrome. Ann Intern Med 1949; 30(1): 121–179. doi: 10.7326/0003-4819-30-1-121.
5. Ahrens EH, Payne MA, Kunkel HG et al. Primary biliary cirrhosis. Medicine 1950; 29 (4): 299–364. doi: 10.1097/00005792-195012000-00002.
6. Sherlock S. Primary billiary cirrhosis (chronic intrahepatic obstructive jaundice). Gastroenterology 1959; 37: 574–586.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51(2): 237–267. doi: 10.1016/ j.jhep.2009.04.009.
8. Lindor KD, Gershwin ME, Poupon R et al. Primary biliary cirrhosis. Hepatology 2009; 50(1): 291–308. doi: 10.1002/hep.22906.
9. Beuers U, Gershwin ME, Gish RG et al. Changing nomenclature for PBC: from “cirrhosis” to “cholangitis”. J Hepatol 2015; 63(5): 1285–1287. doi: 10.1016/j.jhep.2015.06.031.
10. Kim WR, Lindor KD, Locke GR et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119(6): 1631–1636. doi: 10.1053/gast.2000.20197.
11. Carbone M, Sharp SJ, Flack S et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016; 63(3): 930–950. doi: 10.1002/hep.28017.
12. Jones DE, Watt FE, Metcalf JV et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 1999; 30(3): 402–407. doi: 10.1016/s0168-8278(99)80097-x.
13. Gershwin ME, Selmi C, Worman HJ et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42(5): 1194–1202. doi: 10.1002/hep.20907.
14. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diag- nosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67(1): 145–172. doi: 10.1016/j.jhep.2017.03.022.
15. Salunga TL, Cui ZG, Shimoda S et al. Oxidative stress-induced apoptosis of bile duct cells in primary biliary cirrhosis. J Autoimmun 2007; 29(2–3): 78–86. doi: 10.1016/j.jaut.2007.04.002.
16. Kumagi T, Onji M. Presentation and diagnosis of primary biliary cirrhosis in the 21st century. Clin Liver Dis 2008; 12(2): 243–259. doi: 10.1016/j.cld.2008.02.014.
17. Jones DE, Bhala N, Burt J et al. Four year follow-up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 2006; 55(4): 536–541. doi: 10.1136/gut.2005.080317.
18. Prince M, Chetwynd A, Newman W et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123(4): 1044–1051. doi: 10.1053/gast.2002.36027.
19. Talwalkar JA, Souto E, Jorgensen RA et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1(4): 297–302.
20. Poupon R, Chazouilleres O, Balkau B et al. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J Hepatol 1999; 30(3): 408–412. doi: 10.1016/s0168-8278(99)80098-1.
21. Phillips JR, Angulo P, Petterson T et al. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96(9): 2745–2750. doi: 10.1111/j.1572-0241. 2001.04134.x.
22. Crippin JS, Lindor KD, Jorgensen R et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992; 15(5): 858–862. doi: 10.1002/hep.1840150518.
23. Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194(2): 293–299. doi: 10.1016/j.atherosclerosis.2006.11.036.
24. Trivedi PJ, Lammers WJ, van Buuren HR et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016; 65(2): 321–329. doi: 10.1136/gutjnl-2014-308351.
25. Lindor KD, Bowlus CL, Boyer J et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2019; 69(1): 394–419. doi: 10.1002/hep.30145.
26. Burt AD. Primary biliary cirrhosis and other ductopenic diseases. Clin Liver Dis 2002; 6(2): 363–380. doi: 10.1016/s1089-3261(02)00010-7.
27. Nakanuma Y, Zen Y, Harada K et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement. Pathol Int 2010; 60(3): 167–174. doi: 10.1111/j.1440-1827.2009.02500.x.
28. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60(8): 646–649. doi: 10.1002/bjs.1800600817.
29. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33 (2): 464–470. doi: 10.1053/jhep.2001.22172.
30. Corpechot C, Carrat F, Poujol-Robert A et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56 (1): 198–208. doi: 10.1002/hep.25599.
31. Huet PM, Vincent C, Deslaurier J et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology 2008; 135 (5): 1552–1560. doi: 10.1053/j.gastro.2008.07.019.
32. Dickson ER, Grambsch PM, Fleming TR et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10(1): 1–7. doi: 10.1002/hep.1840100102.
33. Grambsch PM, Dickson ER, Kaplan M et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989; 10(5): 846–850. doi: 10.1002/hep.1840100516.
34. Lammers WJ, van Buuren HR, Hirschfield GM et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147(6): 1338.e5–1349.e5. doi: 10.1053/ j.gastro.2014.08.029.
35. Poupon RE, Balkau B, Eschwege E et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC study group. N Engl J Med 1991; 324(22): 1548–1554. doi: 10.1056/NEJM199105 303242204.
36. Murillo Perez CF, Harms MH, Lindor KD et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol 2020; 115(7): 1066–1074. doi: 10.14309/ajg.0000000000000557.
37. Harms MH, van Buuren HR, Corpechot C et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2019; 71(2): 357–365. doi: 10.1016/j.jhep.2019.04.001.
38. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130(3): 715–720. doi: 10.1053/j.gastro.2005.12.029.
39. Corpechot C, Abenavoli L, Rabahi N et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48(3): 871–877. doi: 10.1002/hep.22428.
40. Lammers WJ, Hirschfield GM, Corpechot C et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015; 149(7): 1804.e4–1812.e4. doi: 10.1053/ j.gastro.2015.07.061.
41. Kumagi T, Guindi M, Fischer SE et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105(10): 2186–2194. doi: 10.1038/ajg.2010.216.
42. Nevens F, Andreone P, Mazzella G et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375(7): 631–643. doi: 10.1056/NEJMoa1509840.
43. Corpechot C, Lemoinne S, Soret PA et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology 2024; 79(1): 39–48. doi: 10.1097/HEP.0000000000000529.
44. Giannini EG, Pasta A, Calabrese F et al. Second-line treatment for patients with primary biliary cholangitis: a systematic review with network meta-analysis. Liver Int 2025; 45(1): e16222. doi: 10.1111/liv.16222.
45. Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales. J Transl Autoimmun 2023; 6: 100188. doi: 10.1016/ j.jtauto.2023.100188.
46. SPC Iqirvo 2025. Souhrn údajů o přípravku. 2025 [online]. Dostupné z: https: //www.ema.europa.eu/cs/documents/product-information/iqirvo-epar-product-information_cs.pdf.
47. Kowdley KV, Bowlus CL, Levy C et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med 2024; 390(9): 795–805. doi: 10.1056/NEJMoa2306185.
48. Bachs L, Pares A, Elena M et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102(6): 2077–2080. doi: 10.1016/0016-5085(92)90335-v.
49. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol 2024; 81(6): 1040–1086. doi: 10.1016/j.jhep.2024.07.032.
50. Singal AK, Guturu P, Hmoud B et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95(5): 755–760. doi: 10.1097/TP.0b013e31827afb3a.
51. Milkiewicz P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis 2008; 12(2): 461–472. doi: 10.1016/j.cld.2008.02.015.
52. Montano-Loza AJ, Hansen BE, Corpechot C et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology 2019; 156(1): 96.e1–107.e1. doi: 10.1053/j.gastro.2018.10.001.